FDG PET-CT in Metastatic Prostate Cancer

Summary

Principal Investigator: H Jadvar
Abstract: Prostate cancer will become an epidemic male health problem due to increasing life expectancy. There is a critical need for accurate imaging evaluation of patients with metastatic prostate cancer. Positron emission tomography (PET) with the most common tracer currently available, [F-18]-fluorodeoxyglucose (FDG), has emerged as an important diagnostic imaging modality in cancer. Recent advances in imaging technology have also resulted in dual-modality PET-CT systems that allow precise fusion of anatomic and metabolic imaging data. Our preliminary in-vitro cell culture, animal in-vivo, and pilot clinical studies have provided compelling evidence that FDG PET may have a significant role in the imaging evaluation of patients with metastatic prostate cancer. There are two specific aims for this research proposal: 1) to assess the diagnostic utility of FDG PET-CT in the evaluation of therapy response in two clinically distinct groups of patients with metastatic prostate cancer, Group I: men with newly diagnosed hormone-naive metastatic disease who will be treated with the standard androgen ablation therapy, and Group II: men with newly developed hormone-refractory metastatic cancer who will be treated with standard chemotherapy, and 2) to evaluate FDG PET-CT in predicting patient outcome. We hypothesize that semi-quantitative FDG PET-CT monitoring of the serial changes in the glucose metabolism of metastatic prostate cancer lesions provides a competitive advantage over the conventional methods in the objective assessment of treatment response and in predicting key clinical outcomes. To test this hypothesis, we will perform a prospective cohort study to evaluate the diagnostic and prognostic utility of serial FDG PET-CT imaging in determining tumor metabolic response to either androgen ablation therapy or to chemotherapy and in predicting key clinical outcomes such as time to hormone-refractory state and survival. Rigorous statistical methods will be applied to determine the diagnostic and prognostic performance of FDG PET-CT in this clinical setting.
Funding Period: ----------------2005 - ---------------2011-
more information: NIH RePORT

Top Publications

  1. pmc [F-18]-Fluorodeoxyglucose PET and PET-CT in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma
    Hossein Jadvar
    Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
    Int J Clin Oncol 13:42-7. 2008
  2. pmc Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer
    Hossein Jadvar
    Division of Nuclear Medicine, Department of Radiology, Kenneth J Norris Jr Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Clin Nucl Med 37:637-43. 2012
  3. pmc Molecular imaging of prostate cancer: PET radiotracers
    Hossein Jadvar
    Department of Radiology, Keck School of Medicine of USC, University of Southern California, 2250 Alcazar St, CsC 102, Los Angeles, CA 90033, USA
    AJR Am J Roentgenol 199:278-91. 2012
  4. pmc PET/CT in prostate cancer: non-choline radiopharmaceuticals
    P Castellucci
    Nuclear Medicine Unit, Policlinico S Orsola Malpighi, Bologna, Italy
    Q J Nucl Med Mol Imaging 56:367-74. 2012
  5. pmc Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations
    Hossein Jadvar
    Division of Nuclear Medicine, Department of Radiology, Keck School of Medicine, University of Southern California, 2250 Alcazar Street, CsC 102, Los Angeles, CA 90033, USA
    Eur J Nucl Med Mol Imaging 40:S5-10. 2013
  6. pmc Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer
    Hossein Jadvar
    Division of Nuclear Medicine, Department of Radiology, Keck School of Medicine of USC, University of Southern California, Los Angeles, California 90033, USA
    J Nucl Med 54:1195-201. 2013
  7. pmc Competitive advantage of PET/MRI
    Hossein Jadvar
    Division of Nuclear Medicine, Department of Radiology, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA, USA Electronic address
    Eur J Radiol 83:84-94. 2014
  8. pmc Targeted α-particle therapy of bone metastases in prostate cancer
    Hossein Jadvar
    From the Divisions of Nuclear Medicine, Department of Radiology, and Cancer Medicine, Department of Medicine, Kenneth J Norris Jr Comprehensive CancerCenter, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA
    Clin Nucl Med 38:966-71. 2013
  9. pmc [F-18]-fluorodeoxyglucose PET-CT of the normal prostate gland
    Hossein Jadvar
    Department of Radiology and Biomedical Engineering, PET Imaging Science Center, University of Southern California, 2250 Alcazar Street, CsC 102, Los Angeles, CA 90033, USA
    Ann Nucl Med 22:787-93. 2008
  10. pmc Choline autoradiography of human prostate cancer xenograft: effect of castration
    Hossein Jadvar
    Molecular Imaging Center, Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Mol Imaging 7:147-52. 2008

Scientific Experts

  • H Jadvar
  • P Castellucci
  • Bhushan Desai
  • Edwin Lin
  • Wafaa Elatre
  • David I Quinn
  • Wei Ye
  • Jacek Pinski
  • Francis S Markland
  • Susan Groshen
  • Stephen Swenson
  • Qingcai Wang

Detail Information

Publications23

  1. pmc [F-18]-Fluorodeoxyglucose PET and PET-CT in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma
    Hossein Jadvar
    Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
    Int J Clin Oncol 13:42-7. 2008
    ..We retrospectively assessed the diagnostic utility of dedicated PET and hybrid PET-CT scans with [F-18]-FDG in the imaging evaluation of recurrent and metastatic bladder transitional cell carcinoma...
  2. pmc Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer
    Hossein Jadvar
    Division of Nuclear Medicine, Department of Radiology, Kenneth J Norris Jr Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Clin Nucl Med 37:637-43. 2012
    ..This study aimed to perform a prospective evaluation of 18F-NaF and 18F-FDG PET/CT in the detection of occult metastatic disease in men with prostate cancer and biochemical relapse...
  3. pmc Molecular imaging of prostate cancer: PET radiotracers
    Hossein Jadvar
    Department of Radiology, Keck School of Medicine of USC, University of Southern California, 2250 Alcazar St, CsC 102, Los Angeles, CA 90033, USA
    AJR Am J Roentgenol 199:278-91. 2012
    ..The imaging evaluation of prostate cancer needs to be tailored to the various phases of this remarkably heterogeneous disease...
  4. pmc PET/CT in prostate cancer: non-choline radiopharmaceuticals
    P Castellucci
    Nuclear Medicine Unit, Policlinico S Orsola Malpighi, Bologna, Italy
    Q J Nucl Med Mol Imaging 56:367-74. 2012
    ....
  5. pmc Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations
    Hossein Jadvar
    Division of Nuclear Medicine, Department of Radiology, Keck School of Medicine, University of Southern California, 2250 Alcazar Street, CsC 102, Los Angeles, CA 90033, USA
    Eur J Nucl Med Mol Imaging 40:S5-10. 2013
    ....
  6. pmc Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer
    Hossein Jadvar
    Division of Nuclear Medicine, Department of Radiology, Keck School of Medicine of USC, University of Southern California, Los Angeles, California 90033, USA
    J Nucl Med 54:1195-201. 2013
    ..The aim of this prospective investigation was to assess the association of parameters derived from baseline (18)F-FDG PET/CT with overall survival (OS) in men with castrate-resistant metastatic prostate cancer...
  7. pmc Competitive advantage of PET/MRI
    Hossein Jadvar
    Division of Nuclear Medicine, Department of Radiology, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA, USA Electronic address
    Eur J Radiol 83:84-94. 2014
    ..Upon clear definition of clinical utility, other important and practical issues related to business operational model, clinical workflow and reimbursement will also be resolved. ..
  8. pmc Targeted α-particle therapy of bone metastases in prostate cancer
    Hossein Jadvar
    From the Divisions of Nuclear Medicine, Department of Radiology, and Cancer Medicine, Department of Medicine, Kenneth J Norris Jr Comprehensive CancerCenter, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA
    Clin Nucl Med 38:966-71. 2013
    ..It is anticipated that, with the current emergence of 223Ra as a viable form of therapy, interest in and use of α-particle therapy in the management of cancer will grow...
  9. pmc [F-18]-fluorodeoxyglucose PET-CT of the normal prostate gland
    Hossein Jadvar
    Department of Radiology and Biomedical Engineering, PET Imaging Science Center, University of Southern California, 2250 Alcazar Street, CsC 102, Los Angeles, CA 90033, USA
    Ann Nucl Med 22:787-93. 2008
    ..We determined the glucose metabolism and computed tomographic (CT) density of the normal prostate gland in relation to age and prostate size on [F-18] fluorodeoxyglucose positron emission tomography (PET)-CT...
  10. pmc Choline autoradiography of human prostate cancer xenograft: effect of castration
    Hossein Jadvar
    Molecular Imaging Center, Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Mol Imaging 7:147-52. 2008
    ..The uptake time interval and castration do not appear to significantly affect the level of radiolabeled choline uptake by the human prostate cancer xenograft...
  11. ncbi Prostate cancer
    Hossein Jadvar
    Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    Methods Mol Biol 727:265-90. 2011
    ..We then review the preclinical and clinical evidence on the potential and emerging role of positron emission tomography with various radiotracers in the imaging evaluation of men with prostate cancer...
  12. pmc Molecular imaging of prostate cancer: a concise synopsis
    Hossein Jadvar
    USC Molecular Imaging Center, Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Mol Imaging 8:56-64. 2009
    ..In this article, we review briefly the contribution of multimodality molecular imaging methods for the in vivo characterization of the pathophysiology of prostate cancer...
  13. pmc Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET
    Hossein Jadvar
    Keck School of Medicine, University of Southern California, 2250 Alcazar Street, CsC 102, Los Angeles, CA 90033, USA
    Nat Rev Urol 6:317-23. 2009
    ..Evidence from animal-based translational and human-based clinical studies points to a potential and emerging role for PET, using F-fluorodeoxyglucose as a radiotracer, in the imaging evaluation of prostate cancer...
  14. pmc 18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization
    Hossein Jadvar
    Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
    J Nucl Med 50:1820-7. 2009
    ....
  15. ncbi The disintegrin contortrostatin in combination with docetaxel is a potent inhibitor of prostate cancer in vitro and in vivo
    Edwin Lin
    Department of Internal Medicine, Norris Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, California 90089, USA
    Prostate 70:1359-70. 2010
    ..The effect of CN in combination with docetaxel on prostate cancer cell lines in vitro and in vivo is evaluated in the present study...
  16. pmc Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline
    Hossein Jadvar
    Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
    J Nucl Med 52:81-9. 2011
    ..In this article, I review the preclinical and clinical evidence on the potential and emerging role of PET with the 3 most commonly studied radiotracers in prostate cancer, namely 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline...
  17. pmc FDG PET/CT Demonstration of Pancreatic Metastasis From Prostate Cancer
    Bhushan Desai
    From the Department of Radiology, PET Imaging Science Center, Keck School of Medicine, University of Southern California, Los Angeles, CA Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA and Division of Cancer Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA
    Clin Nucl Med 36:961-2. 2011
    ..PET/CT in this case helped with the targeted pathologic confirmation to differentiate primary pancreatic tumor from an unusual metastasis from prostate cancer which in turn affected the clinical management...
  18. ncbi Colonic FDG uptake pattern in subjects receiving oral contrast with no known or suspected colonic disease
    Hossein Jadvar
    Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Clin Nucl Med 36:754-6. 2011
    ..We assessed the pattern of metabolic activity in the colon of subjects who received oral contrast and had no known or suspected colonic disease...